409 results on '"Cohrs, Rachel"'
Search Results
202. Gottlieb Boasts Record Generic Approvals; AAM Says Not Enough
203. Newly Elected Democratic Governors Talked Tough On Rx Drug Pricing
204. Vermont Explores Buying Medicaid Rx Drugs From Wholesalers
205. AbbVie, Momenta Settle To Delay Sixth Humira Biosimilar
206. Many Top Pharma-Backed Incumbents In Competitive Races Lose
207. State Lawmakers Will Retool Rx Drug Rate-Setting Commission Bills
208. CAHC To FDA : Stop Studying Rx Drug Imports
209. S&P Global : Part B Changes May Affect Pharma Less Than Other Reforms
210. 10 Ways & Means Republicans Depart, Doggett Likely Health Chair
211. FDA Approves Novartis’ Biosimilar Of AbbVie’s Blockbuster Humira
212. Oklahoma Signs Third Outcome-Based Contract, For Epilepsy Drug
213. Azar Doubts PhRMA Will Play Chicken On Medicare Part B Rx Drugs
214. Price Referencing Decided, Other Details Open To Feedback
215. OMB Official : Congress ‘Did Violence’ To Medicare Part D Donut Hole
216. OMB Official : ‘No Regs Or Policies’ Can Deter Value-Based Drug Pay
217. Maryland AG Asks SCOTUS To Uphold Generic Rx Price Law
218. Michigan Pursues Outcomes-Based Contracts For Medicaid Rx Pricing
219. New Patent Appeal Standard Praised By PhRMA, BIO; Rankles Generics
220. Kavanaugh To Play Role In Drug Patent, Pharma Liability Cases
221. FDA Panel Urges Approval Of Celltrion’s Rituxan Biosimilar
222. FDA Will Reject Sham Citizen Petitions; Refer Cases To FTC
223. Track-And-Trace Could Be Major Problem For State Importation Plans
224. Pallone Wants CREATES, Pay-For-Delay Ban; Ridicules Rebate Rule
225. Many Skeptical About 340B Reform Next Congress, But Carter Optimistic
226. Majority rules: Senate procedures allow Democrats to push targeted policies
227. COVID-19 surprise billing ban may offer lessons for 2022
228. Becerra has sought to rein in consolidation, control prices
229. Pressure builds on Congress to act as COVID-19 spikes again
230. ACA backers feeling more hopeful after Supreme Court hearing
231. Regulatory machine would power Biden's healthcare agenda
232. Campaign spending skewed toward Democrats
233. What a Schumer-led Senate would mean for the industry
234. Private equity-backed dermatology groups got COVID-19 small-biz loans
235. Congressional, state elections will drive healthcare policy agendas
236. Decision 2020: Wide divide on health policy agendas
237. Hospital leaders skeptical of using cost savings to set price for remdesivir
238. Hospitals wrangle with fractured federal COVID-19 aid system
239. HHS slow sending relief funds to Medicaid providers
240. Looming Medicaid cuts could hit providers hard
241. Hospital, business groups urge COBRA subsidies for furloughed workers
242. Massachusetts hospitals work to fix feds' botched remdesivir handout
243. COVID-19 leaves primary care in dire straits
244. HHS issuing $40B in CARES Act checks, but some providers may still miss out
245. Providers set to get billions from COVID-19 relief package
246. ACA heads back to the Supreme Court in the fall
247. Democrats talking up big reforms, but voters are more worried about pocketbook issues
248. Budget deal gives providers some relief.
249. Record-breaking stimulus cash, court drama and a new president.
250. Health policy leaders urge Biden to support 'vulnerable communities'.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.